Peptides DB
Research-centric peptide and protocol reference hub
Study 8 of 29Pasireotide literatureEndocrine · Observational2026

Pasireotide induces proteins related to autophagy in cancer cells.

Pasireotide induces the expression of autophagy-related proteins in cancer cells, but the clinical relevance of these findings is unclear without further studies.

Read at EndocrineAdd to compare

Where it sits

this study against the rest of the pasireotide corpus
1
Preclinical
20
Observational · this one
0
Open-label
3
Randomised
5
Reviews

Summary and findings

This study investigated the effects of Pasireotide (PAS) on autophagy-related proteins in MDA-MB-468 and HeLa cancer cells. The cells were exposed to PAS or a vehicle control for 8, 24, and 32 hours. The findings indicated that PAS treatment induced the expression of several autophagy-related proteins.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Endocrine supplied them

<h4>Purpose</h4>To investigate the possibility that Pasireotide (PAS), which is a synthetic somatostatin analog (SSA), induces proteins related to autophagy in cancer cells.<h4>Methods</h4>MDA-MB-468 and HeLa human cancer cells were exposed to PAS or vehicle for 8, 24 and 32 h, to assess possible effects in autophagy-related proteins. Western blot analysis was utilized to assess changes in protein expression levels due to PAS exposure.<h4>Results</h4>PAS treatment induces the expression of the autophagy-related protein (ATG)-3, ATG-7, and Beclin-1 in MDA-MB-468 and HeLa cells.<h4>Conclusions</h4>Our findings suggest that the beneficial effects of PAS in cancers may involve autophagy. Further studies will attempt to elucidate the underlying mechanisms mediating those effects.

Background

This paper addresses the role of Pasireotide, a synthetic somatostatin analog, in inducing autophagy-related proteins in cancer cells. Previous research has indicated that autophagy may play a role in cancer progression and treatment responses. Understanding how PAS influences autophagy could provide insights into its potential mechanisms of action in cancer therapy.

Methods

The study utilized MDA-MB-468 and HeLa human cancer cell lines, exposing them to Pasireotide or a vehicle control for durations of 8, 24, and 32 hours. The primary outcome measure was the expression of autophagy-related proteins assessed through Western blot analysis.

Results

The study reports that Pasireotide treatment induces the expression of autophagy-related proteins ATG-3, ATG-7, and Beclin-1 in both MDA-MB-468 and HeLa cells. Specific numeric findings regarding the extent of these changes were not reported.

Interpretation

While the findings suggest that Pasireotide may influence autophagy in cancer cells, the lack of quantitative data limits the ability to assess the clinical significance of these effects. The results should be interpreted cautiously, as they do not provide direct evidence of therapeutic benefit or mechanism. Further studies are necessary to determine the relevance of these findings in clinical settings.

Key findings

  • Induced expression of ATG-3 in MDA-MB-468 and HeLa cells.
  • Induced expression of ATG-7 in MDA-MB-468 and HeLa cells.
  • Induced expression of Beclin-1 in MDA-MB-468 and HeLa cells.

Limitations

  • No quantitative data reported.
  • Lack of clinical outcomes.
  • In vitro study, results may not translate to clinical settings.
  • Short exposure times may not reflect long-term effects.

Elsewhere in the Pasireotide corpus

BRecurrent Cushing's disease due to postoperative seeding of tumor cells in the sphenoid sinus: a case report with review of the literature.Endocrine journal · 2026 · n=1 · Not reported in abstract.HumanBPasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.Pituitary · 2026 · n=6 · Median follow-up of 3.3 years (range 0.5 to 5.9).HumanBPredictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.Journal of neuroendocrinology · 2023 · n=44 · No significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).In vitroCPredictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.Journal of neuroendocrinology · 2026 · No significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).In vitroBApproach to the patient: precision medicine-guided evaluation and treatment of acromegaly.The Journal of clinical endocrinology and metabolism · 2026 · 80% of patients achieved hormonal control with biomarker-guided treatment.reviewBTirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.Endocrine journal · 2026 · n=1 · HbA1c decreased from 7.7% to 6.3% after switching to tirzepatide.Human